With Cary Miller, Kun Wang
On February 9, 2012, in a much anticipated press release, FDA announced the publication of draft guidance documents relating to the development of follow-on biologics for previously approved therapeutic proteins under the Biologics Price Competition and Innovation Act (the BPCIA)